Close
Achema middle east
swop processing & packaging

FDA approves new indication for Novartis drug Afinitor

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Overcoming Scale Up Bottlenecks in Cell Culture Bioprocesses

Overcoming Scale Up Bottlenecks in Cell Culture and Downstream...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Optimizing DMF Quality for Successful Health Authority Filings

A Drug Master File (DMF) is a confidential regulatory...

Novartis announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority review designation providing a shortened review period for drugs that treat serious conditions and offer a significant improvement in safety or effectiveness.

Bruno Strigini, President, Novartis Oncology said, Afinitor is the first treatment approved for progressive, nonfunctional NET of lung origin, and one of very few options available for progressive, nonfunctional GI NET, representing a shift in the treatment paradigm for these cancers.

 

Latest stories

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Overcoming Scale Up Bottlenecks in Cell Culture Bioprocesses

Overcoming Scale Up Bottlenecks in Cell Culture and Downstream...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Optimizing DMF Quality for Successful Health Authority Filings

A Drug Master File (DMF) is a confidential regulatory...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »